QQ客服 官方微博 反馈留言

	Study on the clinical efficacy of specific phosphodiesterase inhibitor in patients with pulmonary hypertension due to left heart disease
	Han, Bing; Wang, Qingli
刊名	EXPERIMENTAL AND THERAPEUTIC MEDICINE
	2018
卷号	16期号:2页码:1175-1186
关键词	specific phosphodiesterase inhibitor pulmonary hypertension due to left heart disease left atrial diameter left ventricular end-diastolic diameter left ventricular ejection fraction pulmonary artery systolic pressure tricuspid annular plane systolic excursion right ventricular fractional area change N-terminal pro-B-type natriuretic peptide hypersensitive C-reactive protein
DOI	10.3892/etm.2018.6310
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4568006
专题	山东大学
作者单位	1.Shandong Univ, Key Lab Cardiovasc Remodeling & Funct Res, Chinese Minist Educ, Qilu Hosp, Jinan 250012, Shandong, Peoples R China. 2.[Han
推荐引用方式 GB/T 7714	Han, Bing,Wang, Qingli. Study on the clinical efficacy of specific phosphodiesterase inhibitor in patients with pulmonary hypertension due to left heart disease[J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE,2018,16(2):1175-1186.
APA	Han, Bing,&Wang, Qingli.(2018).Study on the clinical efficacy of specific phosphodiesterase inhibitor in patients with pulmonary hypertension due to left heart disease.EXPERIMENTAL AND THERAPEUTIC MEDICINE,16(2),1175-1186.
MLA	Han, Bing,et al."Study on the clinical efficacy of specific phosphodiesterase inhibitor in patients with pulmonary hypertension due to left heart disease".EXPERIMENTAL AND THERAPEUTIC MEDICINE 16.2(2018):1175-1186.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。